Breast Cancer Trial, Not Yet Recruiting NCT06925529 Sponsor: Baker Heart and Diabetes Institute Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT06925529
Not Yet Recruiting Not Applicable 🇦🇺 Australian site

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person must be female.
  • The person must be between 45 and 75 years old at the time of enrolling in the study.
  • The person must have been diagnosed with stage 1, 2, or 3 breast cancer between 5 and 10 years before enrolling in the study.
  • The person must have received certain types of chemotherapy or radiation treatment, specifically: anthracycline (at any dose), OR trastuzumab (also known as Herceptin) for breast cancer with the HER2 gene mutation, OR tyrosine kinase inhibitors (such as sunitinib), OR radiotherapy to the left side of the chest.
  • The person must have at least one traditional heart disease risk factor, such as high blood pressure, high cholesterol, diabetes, obesity, smoking, or a family history of heart disease.
  • The person must currently be physically inactive, meaning they are not meeting Australian physical activity guidelines for adults and are not regularly doing structured exercise.
  • The person must be eligible for Medicare.
  • The person must be willing to sign a written consent form to take part in the study.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have already been diagnosed with cardiovascular disease (heart or blood vessel disease) or stage B heart failure.
  • People who have been diagnosed with a brain or nervous system condition affecting thinking or memory, or a condition affecting blood flow to the brain.
  • People who have been diagnosed with atrial fibrillation or any other irregular heart rhythm.
  • People with a BMI of 18.4 or below (confirm with trial site).
  • People for whom exercise testing or training would be considered unsafe based on medical screening.
  • People who are not able to speak and understand English.
  • People for whom a brain MRI scan is not safe or suitable (confirm with trial site).
  • People who are already taking part in another clinical trial where being assigned to a different treatment group would be a problem.
  • People with a life expectancy of 12 months or less due to cancer or any other medical condition, or people with any other medical condition — including pregnancy — where the lead researcher determines that joining the trial would not be appropriate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Erin Howden, A/Professor, Baker Heart and Diabetes Institute

Phone: +61 38532 1861

Australian sites

Baker Heart and Diabetes Institute, Melbourne, Victoria
613 8532 1709

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Baker Heart and Diabetes Institute
Registry
ClinicalTrials.gov
Start date
3 November 2025
Est. completion
6 July 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change from Baseline in Neurovascular Function Measured via MRI-Derived Total Cerebral Blood Flow at 6 Months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov